View all the latest information in acute myeloid leukemia, arranged by trials and clinical studies. Listed below are recently added trial updates.
Venetoclax plus hypomethylating agents for the treatment of chemotherapy-ineligible or high-risk AML
Patients with newly diagnosed acute myeloid leukemia who are ineligible or do not respond well to...
What is the impact of venetoclax combinations on the QoL of unfit, elderly patients with AML?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to...
Phase III LACEWING trial of gilteritinib in combination with azacitidine fails to meet its primary endpoint
On December 21, 2020, it was announced that the phase III LACEWING trial (NCT02752035)...
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
Alexander Perl of the University of Pennsylvania, Abramson Comprehensive Cancer Center, Philadelphia, PA, US, and colleagues,...
Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Alexander Perl,...
Gilteritinib in FLT3 AML
Interview with Steering Committee Member Naval Daver about gilteritinib for the treatment of FLT3 AML.
TP53 mutations linked to increased immune infiltration and IFN-γ signaling in patients with AML
Patients with acute myeloid leukemia (AML) are considered to be in the high cytogenetic risk category if...
Editorial theme: TP53-mutant AML
Tumor protein 53 (TP53) is a tumor suppressor protein that binds to DNA, acts as a transcription factor, and induces cell cycle arrest, apoptosis, and cellular...